Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270444 | 1.00 | HTR1A (0.37) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL26213163 | 0.92 | KDM4E (0.41) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL30270527 | 0.89 | KDM4E (0.35) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL26213175 | 0.88 | SRC (0.46) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL26213183 | 0.87 | HTR1A (0.43) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL30270448 | 0.86 | ADRA1A (0.43) | HTR1AHTR7DRD2HTR6SIGMAR1 | |
| SCHEMBL26213178 | 0.84 | HTR7 (0.47) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL26213063 | 0.83 | EPHX2 (0.51) | HTR7KDM1AHDAC6EPHX2SIGMAR1 | |
| SCHEMBL28971521 | 0.82 | SRC (0.39) | HTR1AHTR7DRD2HTR6KDM4E | |
| SCHEMBL26213077 | 0.82 | KDM1A (0.47) | HTR1AHTR7DRD2HTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | HTR1A 448/4885HTR7 414/4885DRD2 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.